Chapter 28 Psychiatry Flashcards

1
Q

5-HT

A

Seratonin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Seratonin acronym

A

5-HT

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

dopamine acronym

A

DA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

MAOI acronym

A

monoamine oxidase inhibitor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

monoamine oxidase inhibitor acronym

A

MAOI

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

MDD vs MDE

A

major depressive disorder vs episode

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

SGA

A

SGA second generation antipsychotics

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

SNRI

A

SNRI serotonin and norepinephrine reuptake inhibitors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

TCA

A

TCA tricyclic antidepressant

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Screening Questions for Major

-pearl from t notes 16

A

• Have you been feeling down, depressed or hopeless?
• Do you feel anxious or worry about things?
• Has there been a time in your life where you have felt euphoric, extremely talkative, had a lot of energy,
and a decreased need for sleep?
• Do you see or hear things that you think other people cannot?
• Have you ever thought of harming yourself or committing suicide?

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Mental state Exam

A
Appearance
Behavior
Conversation (thought form and content ex:delusions)
Affect, mood
Perception (hallucination)
Cognition
Judgement
Insight
Rapport
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Multiaxial Assessment

A

Axis I: differential diagnosis of DSM-5 clinical disorders
• Axis II: personality disorders, developmental disability
• Axis III: general medical conditions potentially relevant to understanding/management of the
mental disorder
• Axis IV: psychosocial and environmental issues
• Axis V: Global Assessment of Functioning (GAF, 0 to 100) incorporating effects of axes I to IV

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Axis I:

A

Axis I: differential diagnosis of DSM-5 clinical disorders

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

• Axis II

A

• Axis II: personality disorders, developmental disability

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Axis III

A

• Axis III: general medical conditions potentially relevant to understanding/management of the
mental disorder

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

• Axis IV:

A

• Axis IV: psychosocial and environmental issues

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

• Axis V:

A

• Axis V: Global Assessment of Functioning (GAF, 0 to 100) incorporating effects of axes I to IV

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

General management in psychiatry, 3 things

A

biological (e.g. pharmacotherapy),

psychological (e.g. CBT), and social (e.g. support group)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What is a delusion?

A

fixed, false beliefs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Hallucinations:

A

Hallucinations: perceptual experiences

without an external stimulus

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Psychotic disorder definition

A
  • characterized by a significant impairment in reality testing
  • delusions or hallucinations
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

3 psychotic disorders based on time

A

brief psychotic disorder >one day to <1 month

schizophreniform disorder 1-6 months

schizophrenia >6months

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Schizophrenia

1epidemiology, Etiology, Pathophysiology, Comorbidity, Management, Course and Prognosis

A
  • prevalence: 0.3-0.7%, M:F = 1:1
  • mean age of onset: females late-20s; males early- to mid-20s
  • suicide risk: 10% die by suicide, 30% attempt suicide
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Schizophrenia

epidemiology, 1Etiology, Pathophysiology, Comorbidity, Management, Course and Prognosis

A

multifactorial: disorder is a result of interaction between both biological and environmental factors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Schizophrenia epidemiology, Etiology, 1Pathophysiology, Comorbidity, Management, Course and Prognosis
* neurodegenerative theory | * neurodevelopmental theory
26
Schizophrenia epidemiology, Etiology, Pathophysiology, 1Comorbidity, Management, Course and Prognosis
• substance-related disorders • anxiety disorders • decreased life expectancy because of associated medical conditions (e.g. weight gain, diabetes, metabolic syndrome, CV/pulmonary disease)
27
Schizophrenia epidemiology, Etiology, Pathophysiology, Comorbidity, 1Management, Course and Prognosis
1 biological / somatic (acute treatment and maintenance: antipsychotics (haloperidol, risperidone, olanzipine, paliperidone; clozapine if refractory); ƒ adjunctive: ± mood stabilizers (for aggression/impulsiveness - lithium, valproate, carbamazepine) ± anxiolytics ± ECT ƒ treat for at least 1-2 years after the first episode, at least 5 years after multiple episodes (relapse causes severe deterioration) 2 psychosocial 3 psychotherapy:
28
Schizophrenia epidemiology, Etiology, Pathophysiology, Comorbidity, Management, 1Course and Prognosis
• majority of individuals display some type of prodromal phase • course is variable: some individuals have exacerbations and remissions and others remain chronically ill; accurate prediction of the long-term outcome is not possible • negative symptoms may be prominent early in the illness and may become more prominent and more disabling later on; positive symptoms appear and typically diminish with treatment • over time: 1/3 improve, 1/3 remain the same, 1/3 worsen
29
neurodegenerative theory
neurodegenerative theory • natural history may be a rapid or gradual decline in function and ability to communicate • glutamate system may mediate progressive degeneration by excitotoxic mechanism which leads to production of free radicals
30
neurodevelopmental theory
• neurodevelopmental theory: abnormal development of the brain from prenatal life • neurons fail to migrate correctly, make inappropriate connections, and break down in later life • inappropriate apoptosis during neurodevelopment resulting in faulty connections between neurons
31
schitzophrenia good prognostic indicators
``` • Acute onset • Shorter duration of prodrome • Female gender • Good cognitive functioning • Good premorbid functioning • No family history • Presence of affective symptoms • Absence of structural brain abnormalities • Good response to drugs • Good support system ```
32
Schizoaffective DSM criteria A
A. concurrent psychosis (criterion A of schizophrenia) and major mood episode - uninterrupted period of illness
33
Schizoaffective DSM criteria B
B. delusions or hallucinations for 2 or more wk in the absence of a major mood episode during the lifetime duration of the illness
34
Schizoaffective DSM criteria C
C. major mood episode symptoms are present for the majority of the total duration of the active and residual periods of the illness
35
Delusional disorder criteria A
A. the presence of one (or more) delusions with a duration of 1 mo or longer
36
Delusional disorder criteria B
B. criterion A for schizophrenia has never been met | Note: hallucinations, if present, are not prominent and are related to the delusional theme
37
Delusional disorder Treatment
• psychotherapy, antipsychotics, antidepressants
38
mood disorders defintion
mood disorders are characterized by the presence of diagnosable mood episodes
39
mood episodes definition
mood episodes represent a combination of symptoms comprising a predominant mood state that is abnormal in quality or duration (e.g. major depressive, manic, mixed, hypomanic). DSM-5 Criteria for mood episodes are listed below.
40
Medical Workup for a Mood Disorder
• routine screening: physical exam, CBC, thyroid function test, extended electrolytes, urinalysis, drug screen, medications list • additional screening: neurological consultation, chest X-ray, ECG, CT head
41
Major Depressive Episode criteria A
≥5 of the following symptoms have been present during the same 2 wk period and represent a change from previous functioning; at least one of the symptoms is either 1) depressed mood or 2) loss of interest or pleasure (anhedonia) ``` MSIGECAPS Mood: depressed Sleep: increased/decreased Interest: decreased Guilt Energy: decreased Concentration: decreased Appetite: increased/decreased Psychomotor: agitation/retardation Suicidal ideation ```
42
Major Depressive Episode criteria B
the symptoms cause clinically significant distress or impairment in social, occupational, or other important areas of functioning
43
Major Depressive Episode criteria C
the episode is not attributable to the direct physiological effects of a substance or a GMC
44
Manic Episode Criteria A
a distinct period of abnormally and persistently elevated, expansive, or irritable mood and abnormally and persistently increased goal-directed activity or energy, lasting ≥1 wk and present most of the day, nearly every day (or any duration if hospitalization is necessary)
45
Manic Episode Criteria B
during the period of mood disturbance and increased energy or activity, ≥3 ``` Criteria for Mania (≥3) GST PAID Grandiosity Sleep (decreased need) Talkative Pleasurable activities, Painful consequences Activity Ideas (flight of) Distractible ```
46
Manic Episode criteria C
the mood disturbance is sufficiently severe to cause marked impairment in social or occupational functioning or to necessitate hospitalization to prevent harm to self or others, or there are psychotic features
47
HypoManic Episode
• criterion A and B of a manic episode is met, but duration is ≥4 d • episode associated with an uncharacteristic change in functioning that is observable by others but not severe enough to cause marked impairment in social or occupational functioning or to necessitate hospitalization • absence of psychotic features. (If these are present the episode is, by definition, manic)
48
Major Depressive Disorder criteria A
presence of a MDE
49
Major Depressive Disorder criteria B
the MDE is not better accounted for by schizoaffective disorder and is not superimposed on schizophrenia, schizophreniform disorder, delusional disorder, or psychotic disorder NOS
50
Major Depressive Disorder criteria C
there has never been a manic episode or a hypomanic episode
51
MDD single vs recurrent
single vs. recurrent is an episode descriptor that carries prognostic significance. Recurrent is classified as the patient having two or more distinct MDE episodes; to be considered separate the patient must have gone 2 consecutive months without meeting criteria
52
MDD 1epidemiology, etiology, risk factors, treatment, prognosis
* lifetime prevalence: 12% | * peak prevalence age 15-25 yr (M:F = 1:2)
53
MDD epidemiology, 1etiology, risk factors, treatment, prognosis
1. biological | 2. psychosocial
54
MDD epidemiology, etiology, 1risk factors, treatment, prognosis
* sex: F>M, 2:1 * family history: depression, alcohol abuse, suicide attempt or completion * childhood experiences: loss of parent before age 11, negative home environment (abuse, neglect) * personality: neuroticism, insecure, dependent, obsessional * recent stressors: illness, financial, legal, relational, academic * lack of intimate, confiding relationships or social isolation * low socioeconomic status
55
MDD epidemiology, etiology, risk factors, 1treatment, prognosis
Treatment • lifestyle: increased aerobic exercise, mindfulness-based stress reduction, zinc supplementation • biological: SSRIs, SNRIs, other antidepressants, somatic therapies (see Pharmacotherapy, PS44, and Somatic Therapies, PS52) ƒ 1st line pharmacotherapy: sertraline, escitalopram, venlafaxine, mirtazapine more options, read toronto notes • psychological ƒ individual therapy (psychodynamic, interpersonal, CBT), family therapy, group therapy • social: vocational rehabilitation, social skills training • experimental: magnetic seizure therapy, deep brain stimulation, vagal nerve stimulation, ketamine
56
MDD epidemiology, etiology, risk factors, treatment, 1prognosis
one year after diagnosis of MDD without treatment: 40% of individuals still have symptoms that are sufficiently severe to meet criteria for MDD, 20% continue to have some symptoms that no longer meet criteria for MDD, 40% have no mood disorder
57
MDD biological Treatment options
ƒ 1st line pharmacotherapy: sertraline, escitalopram, venlafaxine, mirtazapine ƒ for partial or non-response can change class or add augmenting agent: buproprion, quetiapine-XR, aripiprazole, lithium ƒ typical response to antidepressant treatment: physical symptoms improve at 2 wk, mood/ cognition by 4 wk, if no improvement after 4 wk at a therapeutic dosage alter regimen ƒ ECT: currently fastest and most effective treatment for MDD. Consider in severe, psychotic or treatment-resistant cases ƒ rTMS: early data support efficacy equivalent to ECT with good safety and tolerability ƒ phototherapy: especially if seasonal component, shift work, sleep dysregulation
58
Persistent Depressive Disorder DSM, what length?
depressed mood for most of the day, for more days than not, as indicated either by subjective account or observation by others, for ≥2 yr
59
MAJOR DEPRESSIVE DISORDER WITH PERIPARTUM ONSET | (POSTPARTUM DEPRESSION) definition
MDD that occurs during pregnancy or in the 4 wk following delivery
60
MAJOR DEPRESSIVE DISORDER WITH PERIPARTUM ONSET (POSTPARTUM DEPRESSION) 1clinical presentation, epidemiology, risk factors, treatment, prognosis
* typically lasts 2-6 mo; residual symptoms can last up to 1 yr * may present with psychosis; rare (0.2%), usually associated with mania, but also with MDE * severe symptoms include extreme disinterest in baby, suicidal and infanticidal ideation
61
MAJOR DEPRESSIVE DISORDER WITH PERIPARTUM ONSET (POSTPARTUM DEPRESSION) clinical presentation, 1epidemiology, risk factors, treatment, prognosis
• occurs in 10% of mothers, risk of recurrence 50%
62
MAJOR DEPRESSIVE DISORDER WITH PERIPARTUM ONSET (POSTPARTUM DEPRESSION) clinical presentation, epidemiology, 1risk factors, treatment, prognosis
Risk Factors • previous history of a mood disorder (postpartum or otherwise), family history of mood disorder • psychosocial factors: stressful life events, unemployment, marital conflict, lack of social support, unwanted pregnancy, colicky or sick infant
63
MAJOR DEPRESSIVE DISORDER WITH PERIPARTUM ONSET (POSTPARTUM DEPRESSION) clinical presentation, epidemiology, risk factors, 1treatment, prognosis
Treatment • psychotherapy (CBT or IPT) • short-term safety of maternal SSRIs for breastfeeding infants established; long-term effects unknown • if depression severe or psychotic symptoms present, consider ECT
64
MAJOR DEPRESSIVE DISORDER WITH PERIPARTUM ONSET (POSTPARTUM DEPRESSION) clinical presentation, epidemiology, risk factors, treatment, 1prognosis
Prognosis • impact on child development: increased risk of cognitive delay, insecure attachment, behavioural disorders • treatment of mother improves outcome for child at 8 mo through increased mother-child interaction
65
Bipolar I Disorder definition
disorder in which at least one manic episode has occurred
66
Bipolar II Disorder definition
disorder in which there is at least 1 MDE, 1 hypomanic and no manic episodes
67
BIPOLAR 1epidemiology, risk factors, treatment, prognosis
lifetime prevalence: 1% BPI, 1.1% BPII, 2.4% Subthreshold BPD; M:F = 1:1 • age of onset: teens to 20s, usually MDE first, manic episode 6-10 years after, average age of first manic episode 32 yr
68
BIPOLAR epidemiology, 1risk factors, treatment, prognosis
genetic: 60-65% of bipolar patients have family history of major mood disorders, especially bipolar disorders • clinical features predictive of bipolar > unipolar diagnosis given history of MDE: early age of onset (<25 yr), increased number of MDEs, psychotic symptoms, postpartum onset, anxiety disorders (espescially separation, panic), antidepressant failure due to early “poop out” or hypomanic symptoms, early impulsivity and aggression, substance abuse, cyclothymic temperament
69
BIPOLAR epidemiology, risk factors, 1treatment, prognosis
• lifestyle: psychoeducation for patient and supports on cycling nature of illness, ensure regular check ins, develop early warning system, “emergency plan” for manic episodes, promote stable routine (sleep, meals, exercise) • biological: lithium, anticonvulsants, antipsychotics, ECT (if refractory); monotherapy with antidepressants should be avoided •psychological: supportive or psychodynamic psychotherapy, CBT, IPT or interpersonal social rhythm therapy, family therapy • social: vocational rehabilitation, consider leave of absence from school/work, assess capacity to manage finances, drug and EtOH cessation, sleep hygiene, social skills training, education and recruitment of family members
70
BIPOLAR epidemiology, risk factors, treatment, 1prognosis
• high suicide rate (15% mortality from suicide), especially in mixed states • BP I and II are chronic conditions with a relapsing and remitting course featuring alternating manic and depressive episodes; depressive symptoms tend to occur more frequently and last longer than manic episodes • can achieve high level of functioning between episodes • may switch rapidly between depression and mania without any period of euthymia in between • high recurrence rate for mania – 90% will have a subsequent episode in the next 5 yr • long term follow up of BP I – 15% well, 45% well with relapses, 30% partial remission, 10% chronically ill
71
Bipolar x is quite often missed and many patients are symptomatic for up to a decade before accurate diagnosis and treatment
II
72
``` Patients with x are at higher risk for suicide when they switch from mania to depression, especially as they become aware of consequences of their behaviour during the manic episode ```
bipolar disorder
73
``` x is among few agents with proven efficacy in preventing suicide attempts and completions and international research has found that populations with higher lithium levels in their drinking water have lower suicide rates in their general population ```
Lithium
74
The 4 L’s for Bipolar Depression
Lithium, Lamotrigine, Lurasidone, | SeroqueL
75
CYCLOTHYMIA 1Diagnosis, Treatment
Diagnosis • presence of numerous periods of hypomanic and depressive symptoms (not meeting criteria for full hypomanic episode or MDE) for ≥2 yr; never without symptoms for >2 mo • never have met criteria for MDE, manic or hypomanic episodes • symptoms are not due to the direct physiological effects of a substance or GMC • symptoms cause clinically significant distress or impairment in social, occupational, or other important areas of functioning
76
CYCLOTHYMIA Diagnosis, 1Treatment
Treatment • similar to Bipolar I: mood stabilizer ± psychotherapy, avoid antidepressant monotherapy, treat any comorbid substance use disorder
77
Anxiety Disorders
Panic Disorder Agoraphobia Generalized Anxiety Disorder Phobic Disorders
78
part of brain responsible for fear conditioning
the amygdala (fear conditioning);
79
Panic disorder criteria A
recurrent unexpected panic attacks - a panic attack is an abrupt surge of intense fear or intense discomfort that reaches a peak within minutes, and during which time four (or more) of the
80
Panic disorder criteria B
1 mo (or more) of “anxiety about panic attacks”
81
STUDENTS FEAR the 3 Cs
``` Criteria for Panic Disorder (≥4) STUDENTS FEAR the 3 Cs Sweating Trembling Unsteadiness, dizziness Depersonalization, Derealization Excessive heart rate, palpitations Nausea Tingling Shortness of breath Fear of dying, losing control, going crazy 3 Cs: Chest pain, Chills, Choking ```
82
Panic Attack vs. Panic Disorder
``` Panic disorder consists of panic attacks + other criteria Panic attack is not a codable disorder and can occur in the context of many different disorders ```
83
Panic Disorder 1Epidemiology, Treatment, Prognosis
* prevalence: 2-5% (one of the top five most common reasons to see a family doctor); M:F = 1:2-3 * onset: average early-mid 20s, familial pattern
84
Panic Disorder Epidemiology, 1Treatment, Prognosis
• psychological ƒ CBT, cognitive restructuring relaxation techniques • pharmacological ƒ SSRIs: fluoxetine, citalopram, paroxetine, fluvoxamine, sertraline ƒ SNRI: venlafaxine ƒ with SSRI/SNRIs start with low doses, titrate up slowly
85
Panic Disorder Epidemiology, Treatment, 1Prognosis
* 6-10 yr post-treatment: 30% well, 40-50% improved, 20-30% no change or worse * clinical course: chronic, but episodic with psychosocial stressors
86
Agoraphobia criteria A
``` A. marked fear or anxiety about two (or more) of the following five situations: ƒ using public transportation ƒ being in open spaces ƒ being in enclosed places ƒ standing in line or being in a crowd ƒ being outside of the home alone ```
87
Agoraphobia criteria B
the individual fears or avoids these situations because of thoughts that escape might be difficult
88
Agoraphobia treatment
• as per panic disorder
89
Agoraphobia Definition
“Anxiety about not being able to escape, > 6 mo”
90
Generalized Anxiety Disorder Criteria A
excessive anxiety and worry (apprehensive expectation), occurring more days than not for at least 6 mo, about a number of events or activities (such as work or school performance)
91
Generalized Anxiety Disorder Criteria B
the individual finds it difficult to control the worry
92
Generalized Anxiety Disorder Criteria C
the anxiety and worry are associated with three (or more) of the following six symptoms (with at least some symptoms having been present for more days than not for the past 6 mo) 1. restlessness or feeling keyed up or on edge 2. being easily fatigued 3. difficulty concentrating or mind going blank 4. irritability 5. muscle tension 6. sleep disturbance (difficulty falling or staying asleep, or restless, unsatisfying sleep)
93
Generalized Anxiety Disorder | 1Epidemiology, Treatment, Prognosis
• 1 yr prevalence: 3-8%; M:F = 1:2 ƒ if considering only those receiving inpatient treatment, ratio is 1:1 • most commonly presents in early adulthood
94
Generalized Anxiety Disorder | Epidemiology, 1Treatment, Prognosis
• lifestyle: caffeine and EtOH avoidance, sleep hygiene • psychological: CBT including relaxation techniques, mindfulness • biological ƒ SSRIs and SNRIs are 1st line (paroxetine, escitalopram, sertraline, venlafaxine XL) ƒ 2nd line: buspirone (tid dosing), bupropion (caution due to stimulating effects), ƒ add-on benzodiazepines (short-term, low dose, regular schedule, long half-life, avoid prn usage) ƒ β-blockers not recommended
95
Generalized Anxiety Disorder | Epidemiology, Treatment, 1Prognosis
• chronically anxious adults become less so with age • depends on pre-morbid personality functioning, stability of relationships, work, and severity of environmental stress • difficult to treat
96
2 Types of phobic disorders
Specific phobia vs Social phobias
97
Specific phobia def
definition: marked and persistent (> 6 mo) fear that is excessive or unreasonable, cued by presence or anticipation of a specific object or situation
98
Social Phobia
definition: marked and persistent (> 6 mo) fear of social or performance situations in which one is exposed to unfamiliar people or to possible scrutiny by others; fearing he/she will act in a way that may be humiliating or embarrassing (e.g. public speaking, initiating or maintaining conversation, dating, eating in public
99
Diagnostic Criteria for Phobic Disorders
• exposure to stimulus almost invariably provokes an immediate anxiety response; may present as a panic attack • person recognizes fear as excessive or unreasonable • situations are avoided or endured with anxiety/distress • significant interference with daily routine, occupational/social functioning, and/or marked distress
100
Phobia disorder treatment
• psychological ƒ cognitive behaviour therapy (focusing on both in vivo and virtual exposure therapy, gradually facing feared situations) ƒ behavioural therapy is more efficacious than medication • biological ƒ SSRIs/SNRIs (e.g. fluoxetine, paroxetine, sertraline, venlafaxine), MAOIs ƒ β-blockers or benzodiazepines in acute situations (e.g. public speaking)
101
Phobia disorder prognosis
chronic
102
OCD criteria A
A. presence of obsessions, compulsions, or both
103
OCD criteria B
B. the obsessions or compulsions are time-consuming (e.g. take >1 h/d) or cause clinically significant distress or impairment in social, occupational, or other important areas of functioning
104
rate of OCD in x is higher than in the general population
first-degree relatives
105
OCD 1Epidemiology, Treatment, Prognosis
* 12 mo prevalence 1.1-1.8%; females affected at slightly higher rates than males * rate of OCD in first-degree relatives is higher than in the general population
106
OCD Epidemiology, 1Treatment, Prognosis
• CBT: exposure with response prevention (ERP) – involves exposure to feared situations with the addition of preventing the compulsive behaviours; cognitive strategies include challenging underlying beliefs • pharmacotherapy: SSRIs/SNRIs (12-16 week trials, higher doses vs. depression), clomipramine; adjunctive antipsychotics (risperidone)
107
OCD Epidemiology, Treatment, 1Prognosis
• tends to be refractory and chronic
108
Acute Stress Disorder
• May be a precursor to PTSD • Similar symptoms to PTSD • Symptoms persist 3 d after a trauma until 1 mo after the exposure
109
PTSD Too many criteria 1Epidemiology, Treatment, Complications
• prevalence of 7% in general population • men’s trauma is most commonly combat experience/physical assault; women’s trauma is usually physical or sexual assault
110
PTSD Too many criteria Epidemiology, 1Treatment, Complications
• psychotherapy, CBT ƒ ensure safety and stabilize: e.g. emotional regulation techniques (e.g. breathing, relaxation) ƒ once coping mechanisms established, can explore/mourn trauma - challenge dysfunctional beliefs, etc. ƒ reconnect and integrate - exposure therapy, etc. • biological ƒ SSRIs (e.g. paroxetine, sertraline) ƒ prazosin (for treating disturbing dreams and nightmares) ƒ benzodiazepines (for acute anxiety) ƒ adjunctive atypical antipsychotics (risperidone, olanzapine) • eye movement desensitization and reprocessing (EMDR): an experimental method of reprocessing memories of distressing events by recounting them while using a form of dual attention stimulation such as eye movements, bilateral sound, or bilateral tactile stimulation (its use is controversial because of limited evidence)
111
PTSD Too many criteria Epidemiology, Treatment, 1Complications
Complications • substance abuse, relationship difficulties, depression, impaired social and occupational functioning disorders, personality disorders
112
Adjustment Disorder definition
a versatile clinical entity designed to capture patients who have difficulty coping with a stressful life event or situation and develop acute, often transient, emotional or behavioural symptoms that resemble less severe versions of other psychiatric conditions
113
Adjustment Disorder Criteria A
the development of emotional or behavioural symptoms in response to an identifiable stressor(s) occurring within 3 mo of the onset of the stressor(s)
114
Adjustment Disorder Criteria B
these symptoms or behaviours are clinically significant as evidenced by either of the following: ƒ marked distress that is in excess of what would be expected from exposure to the stressor ƒ significant impairment in social or occupational (academic) functioning
115
Adjustment Disorder 1Classification, Epidemiology, Treatment
• types of stressors ƒ single (e.g. termination of romantic relationship) ƒ multiple (e.g. marked business difficulties and marital problems) ƒ recurrent (e.g. seasonal business crises) ƒ continuous (e.g. living in a crime-ridden neighbourhood) ƒ developmental events (e.g. going to school, leaving parental home, getting married, becoming a parent, failing to attain occupational goals, retirement)
116
Adjustment Disorder Classification, 1Epidemiology, Treatment
• F:M 2:1, prevalence 2-8% of the population
117
Adjustment Disorder Classification, Epidemiology, 1Treatment
• brief psychotherapy: individual or group (particularly useful for patients dealing with unique and specific medical issues; e.g. colostomy or renal dialysis groups), crisis intervention • biological ƒ benzodiazepines may be used for those with significant anxiety symptoms (short-term, lowdose, regular schedule)
118
Bereavement define
Clinical Presentation • bereavement is a normal psychological and emotional reaction to a significant loss, also called grief or mourning
119
Risk Factors for Poor Bereavement | Outcome
``` • Poor social supports • Unanticipated death or lack of preparation for death • Highly dependent relationship with deceased • High initial distress • Other concurrent stresses and losses • Death of a child • Pre-existing psychiatric disorders, especially depression and separation anxiety ```
120
• if a patient meets criteria for MDD, even in the context of a loss or bereavement scenario
• if a patient meets criteria for MDD, even in the context of a loss or bereavement scenario, they are still diagnosed with MDD
121
presence of the following symptoms may indicate abnormal grief/presence of MDD
ƒ guilt about things other than actions taken or not taken by the survivor at the time of death ƒ thoughts of death other than the survivor feeling that they would be better off dead or should have died with the deceased person; morbid preoccupation with worthlessness ƒ marked psychomotor retardation; prolonged and marked functional impairment ƒ hallucinatory experiences other than thinking that the survivor hears the voice of or transiently sees the image of the deceased person ƒ dysphoria that is pervasive and independent of thoughts or triggers of the deceased, absence of mood reactivity
122
after 12 mo, if patient continues to yearn/long for the deceased, experience intense sorrow/ emotional pain in response to the death, remain preoccupied with the deceased or with their circumstance of death, then may start to consider a diagnosis of “x”
persistent complex bereavement | disorder
123
Treatment of bereavement
• support and watchful waiting should be first line, as well as education and normalization of the grief process • screen for increased alcohol, cigarette and drug use • normal grief should not be treated with antidepressant or antianxiety medication, as it is important to allow the person to experience the whole mourning process to achieve resolution • psychosocial: for those needing additional support, complex grief/bereavement, or significant MDD, grief therapy (individual or group) is indicated • pharmacotherapy: MDD present, past history of mood disorders, severe or autonomous symptoms
124
Neurocognitive Disorders
Delirium | Major Neurocognitive Disorder (Dementia)
125
Delerium | DSM criteria A
attention and awareness: disturbance in attention (i.e. reduced ability to direct, focus, sustain, and shift attention) and awareness (reduced orientation to the environment)
126
Delerium | DSM criteria B
acute and fluctuating: disturbance develops over short period of time (usually hours to days), represents a change from baseline attention and awareness, and tends to fluctuate in severity during the course of a day
127
Delerium | DSM criteria C
cognitive changes: an additional disturbance in cognition (e.g. memory deficit, disorientation, language, visuospatial ability, or perception)
128
Delerium | DSM criteria D
not better explained: disturbances in criteria A and C are not better explained by another neurocognitive disorder (pre-existing, established, or evolving) and do not occur in the context of a severely reduced level of arousal (e.g. coma)
129
Delerium | DSM criteria E
direct physiological cause: evidence that disturbance is a direct physiological consequence of another medical condition, substance intoxication or withdrawal (i.e. due to a drug of abuse or medication), toxin, or is due to multiple etiologies
130
Delerium Risk Factors
* hospitalization (incidence 10-56%) * previous delirium * nursing home residents (incidence 60%) * polypharmacy (e.g. anticholinergic) * old age (especially males) * severe illness (e.g. cancer, AIDS) * recent anesthesia or surgery * substance abuse * pre-existing cognitive impairment, brain pathology,psychiatric illness
131
Delerium Acronym
I WATCH DEATH
132
I WATCH DEATH I
Infectious (encephalitis, meningitis, UTI, pneumonia)
133
I WATCH DEATH W
Withdrawal (alcohol, barbiturates, benzodiazepines)
134
I WATCH DEATH 2A
Acute metabolic disorder (electrolyte imbalance, hepatic or renal failure) Acute vascular (shock, vasculitis, hypertensive encephalopathy)
135
I WATCH DEATH 2T
Trauma (head injury, post-operative) Toxins: substance use, sedatives, opioids (especially morphine), anesthetics, anticholinergics, anticonvulsants, dopaminergic agents, steroids, insulin, glyburide, antibiotics (especially quinolones), NSAIDs
136
I WATCH DEATH C
CNS pathology (stroke, hemorrhage, tumour, seizure disorder, Parkinson’s)
137
I WATCH DEATH 2H
Hypoxia (anemia, cardiac failure, pulmonary embolus) Heavy metals (arsenic, lead, mercury)
138
I WATCH DEATH D
Deficiencies (vitamin B12, folic acid, thiamine)
139
I WATCH DEATH E
Endocrinopathies (thyroid, glucose, parathyroid, adrenal)
140
Delerium Inx
Investigations • standard: CBC and differential, electrolytes, Ca2+, PO4 3-, Mg2+, glucose, ESR, LFTs, Cr, BUN, TSH, vitamin B12, folate, albumin, urine C&S, R&M • as indicated: ECG, CXR, CT head, toxicology/heavy metal screen, VDRL, HIV, LP, blood cultures, EEG (typically abnormal - generalized slowing or fast activity, can also be used to rule out underlying seizures or post-ictal states as etiology) • indications for CT head: focal neurological deficit, acute change in status, anticoagulant use, acute incontinence, gait abnormality, history of cancer
141
Delerium managmeent
Management • intrinsic ƒ identify and treat underlying cause immediately ƒ stop all non-essential medications ƒ maintain nutrition, hydration, electrolyte balance and monitor vitals • extrinsic ƒ environment: quiet, well-lit, near window for cues regarding time of day ƒ optimize hearing and vision ƒ room near nursing station for closer observation; constant care if patient jumping out of bed, pulling out lines ƒ family member present for reassurance and re-orientation ƒ frequent orientation - calendar, clock, reminders • biological ƒ low dose, high potency antipsychotics: haloperidol has the most evidence; reasonable alternatives include risperidone, olanzapine (more sedating, less QT prolongation), quetiapine (if EPS), aripiprazole ƒ benzodiazepines only to be used in alcohol withdrawal delirium; otherwise, can worsen delirium ƒ try to minimize anticholinergic side effects • physical restraints if patient becomes violent
142
Delerium Prognosis
• up to 50% 1 yr mortality rate after episode of delirium
143
Another term for dementia
Major Neurocognitive Disorder
144
The 4 As of Dementia
``` The 4 As of Dementia Amnesia Aphasia Apraxia Agnosia ```